Lexaria Historical Cash Flow
| LEXXW Stock | USD 0.55 0.05 8.33% |
Analysis of Lexaria Bioscience cash flow over time is an excellent tool to project Lexaria Bioscience Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Capital Expenditures of 36.8 K or Total Cash From Financing Activities of 12.5 M as it is a great indicator of Lexaria Bioscience ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Lexaria Bioscience Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Lexaria Bioscience Corp is a good buy for the upcoming year.
Lexaria |
About Lexaria Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Lexaria balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Lexaria's non-liquid assets can be easily converted into cash.
Lexaria Bioscience Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Lexaria Bioscience Corp to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Lexaria Bioscience operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Lexaria Bioscience's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Lexaria Bioscience Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexaria Bioscience Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. At this time, Lexaria Bioscience's Change In Cash is fairly stable compared to the past year. Change In Working Capital is likely to climb to about 100.7 K in 2025, whereas Capital Expenditures is likely to drop slightly above 36.8 K in 2025.
| 2022 | 2023 | 2024 | 2025 (projected) | Begin Period Cash Flow | 5.8M | 1.4M | 1.6M | 1.8M | End Period Cash Flow | 1.4M | 6.5M | 7.5M | 7.8M |
Lexaria Bioscience cash flow statement Correlations
Click cells to compare fundamentals
Lexaria Bioscience Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Lexaria Bioscience cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 9.6M | (5.1M) | (4.5M) | 5.1M | 5.9M | 6.2M | |
| Free Cash Flow | (4.1M) | (5.0M) | (6.1M) | (5.0M) | (4.5M) | (4.2M) | |
| Change In Working Capital | 63.5K | (351.5K) | 143.3K | 106.6K | 95.9K | 100.7K | |
| Other Cashflows From Financing Activities | 4.0M | (44.6K) | (169.6K) | 6.1M | 7.0M | 7.4M | |
| Capital Expenditures | 79.5K | 131.4K | 169.6K | 43.0K | 38.7K | 36.8K | |
| Total Cash From Operating Activities | (4.0M) | (4.9M) | (5.9M) | (5.0M) | (4.5M) | (4.2M) | |
| Net Income | (4.2M) | (7.4M) | (6.7M) | (5.8M) | (5.2M) | (5.0M) | |
| Total Cash From Financing Activities | 13.4M | (44.6K) | 1.6M | 10.3M | 11.9M | 12.5M | |
| End Period Cash Flow | 10.9M | 5.8M | 1.4M | 6.5M | 7.5M | 7.8M | |
| Begin Period Cash Flow | 1.3M | 10.9M | 5.8M | 1.4M | 1.6M | 1.8M | |
| Depreciation | 147.6K | 141.3K | 145.4K | 76.2K | 68.5K | 97.0K | |
| Other Non Cash Items | 92.9K | 2.0M | 530.3K | 174.7K | 200.9K | 190.9K | |
| Change To Account Receivables | 189.6K | (137.5K) | 26.5K | (35.6K) | (32.0K) | (33.6K) | |
| Stock Based Compensation | 410.0K | 752.6K | 170.4K | 492.2K | 566.1K | 538.4K | |
| Change To Inventory | 4.2K | 95.0K | (2.0K) | 43.1K | 49.5K | 52.0K | |
| Other Cashflows From Investing Activities | 273.4K | (49.2K) | (135.9K) | (188.6K) | (169.7K) | (161.3K) | |
| Investments | (26.8K) | 193.9K | (180.6K) | (169.6K) | (195.1K) | (204.8K) | |
| Issuance Of Capital Stock | 2.7M | 9.5M | 0.0 | 1.6M | 1.4M | 2.4M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.